Mr Eduardo Pisani
Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
Mr Eduardo Pisani became Director General of the IFPMA at the
end of 2009. He came to the IFPMA from Bristol-Myers Squibb, a
company he joined in 2001, and in which he had risen to the
position of Vice President, International Policy and Government
Affairs. Prior to that, Mr. Pisani held positions as legal counsel at
Immuno AG in Belgium and Austria, at Baxter Healthcare in Belgium
and Italy, and in European Policy and Government Affairs at
Adamson Associates and SmithKline Beecham in Belgium. He
started his career in 1989, in the marketing department of Lederle
France. Mr. Pisani graduated in Law at the University of Catania,
As IFPMA Director General, Mr Pisani leads the dialogue between
research-based pharmaceutical companies and associations with
the United Nations and its specialized agencies. Together with his
team and working with IFPMA President and Vice Presidents, Mr
Pisani shares the expertise and perspectives of the industry in
global health discussions.
Mr Pisani believes that platforms for constructive policy discussion
are essential to effective policy making and to public health, and
has been instrumental in shaping many of IFPMA’s leading
initiatives such as those on NCDs and on NTDs.
Dr Shiro Konuma
Director of Global Health Policy Division, Ministry of Foreign Affairs, Japan, Board Member, Global Health Innovative Technology Fund (GHIT)
Dr. Shiro Konuma is currently Director of Global Health Policy
Division at the Ministry of Foreign Affairs of Japan.
He graduated from the Faculty of Medicine, University of Tokyo in
1992 and worked for the University of Tokyo Hospital until joining
the Japanese diplomatic service in 1994. In 1996, he studied at
INSEAD in France.
Prior to his current assignment, he was Counsellor of the
Permanent Mission of Japan in Geneva, responsible for
development and macro-economic issues in the WTO and other
trade related organizations.
Ms. Caroline T. Roan
Vice President, Corporate Responsibility, Pfizer Inc., President, The Pfizer Foundation
Ms Caroline Roan is Vice President of Corporate Responsibility at
Pfizer Inc, headquartered in New York. She is also President of ‘The
Ms Roan has direct oversight of Pfizer’s Corporate Responsibility
(CR) function, including stakeholder engagement, reporting, and the
design of social investment strategies. During her tenure, Pfizer has
refined its CR strategy to better support the company’s evolving
business priorities and communicate more effectively with investors
and other stakeholders about how Pfizer integrates CR issues into its
Ms Roan has spearheaded Pfizer’s adoption of more innovative
public reporting on responsibility issues. This has included the
publication of Pfizer’s award-winning first “one report” which
combined the annual and corporate responsibility reports. In
addition, she led the team that launched “Get Old,” an initiative
designed to improve connection with consumers via social media.
Under Ms Roan’s leadership, Pfizer continues to be a top corporate
donor and has received local, national and international awards and
recognition for its corporate responsibility programs.
In 2012 Ms Roan was selected to serve as a David Rockefeller Fellow
through the Partnership for New York City.
Ms Roan received her Bachelor of Arts in sociology and anthropology
from Earlham College, Richmond, Indiana, and her Masters of Public
Policy from the School of International and Public Affairs, Columbia
Dr Aron Cramer
President and CEO, Business Social Responsibility (BSR)
Dr Aron Cramer is recognized globally as a preeminent authority on
corporate responsibility and sustainability strategy by business, NGOs,
and the public sector. Under his leadership, BSR has doubled its staff
and expanded its global presence, which currently includes offices in
Beijing, Copenhagen, Guangzhou, Hong Kong, Paris, São Paulo, New
York, and San Francisco.
On a day-to-day basis, Dr Cramer advises senior executives at more
than 250 member companies and other global businesses, and
regularly is featured as a speaker at major events and in a range of toptier
He is co-author of the book Sustainable Excellence: The Future of
Business in a Fast-Changing World, which spotlights some of the
sustainability strategies that drive business success.
Dr Cramer joined BSR in 1995 as the founding director of its business
and human rights program, and opened BSR’s Paris office in 2002,
where he worked until assuming his current role as President and CEO
Previously he practiced law in San Francisco, and worked as a journalist
at ABC News in New York.
Dr Mel Spigelman
President and Chief Executive Officer, Global Alliance for TB Drug Development (TB Alliance)
Dr. Spigelman is the President and Chief Executive Officer of the
Global Alliance for TB Drug Development (TB Alliance). Prior to being
appointed President and CEO in 2009, Dr. Spigelman served for five
and a half years as the Director of Research and Development at the
TB Alliance. A highly regarded expert in domestic and international
drug research and development, Dr. Spigelman previously spent a
decade managing drug R&D at Knoll Pharmaceuticals (a division of
BASF Pharma). As Vice President of R&D at Knoll for eight years, Dr.
Spigelman directed clinical development and supervised all R&D
activities from basic discovery to regulatory approval and Medical
Affairs. He established global R&D processes as part of Knoll's senior
R&D management team, oversaw a marked increase in US regulatory
filings and approvals, and supervised joint R&D programs with multiple
other pharmaceutical companies.
Dr. Spigelman received his undergraduate degree from Brown
University and his medical degree from the Mt. Sinai School of
Medicine where he specialized in Internal medicine, Neoplastic
Diseases and Preventive Medicine. Dr. Spigelman holds board
certifications from the American Board of Internal Medicine, the
American Board's Subspecialty Board of Medical Oncology, and the
American Board of Preventive Medicine and was the recipient of the
American Cancer Society Clinical Oncology Career Development Award
Presently, Dr. Spigelman serves on the Coordinating Board of the WHO
Stop TB Partnership, is Co-chair of the Working Group on New Drugs
of the WHO Stop TB Partnership, and is a member of the Governing
Board of the Tres Cantos Open Lab, GlaxoSmithKline.
24th Sep 2013
6:30 pm - 8:00 pm UTC−05:00
Pfizer Inc., Conference Room ‘Times Square’, building 219, 4th floor